Overview

Extension Study of GI198745 to Treat Benign Prostatic Hyperplasia

Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the safety of GI198745 0.05mg, 0.5mg, 2.5mg once daily for 52 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Dutasteride